Volpara Health Technologies Ltd. announced a distribution agreement to sell Lunit's AI solutions for mammography. Lunit's AI-powered Lunit INSIGHT for early detection of breast cancer will be featured as part of the company's expanded software suite at the 2024 European Congress of Radology (ECR). The suite also includes tools for assessing breast density, evaluating cancer risk, and ensuring mammography quality.

Volpara and Lunit commenced negotiating this distribution agreement prior to entering into a Scheme Implementation Agreement on 14 December 2023 (SIA). This distribution agreement is important to Volpara's ongoing business regardless of whether Lunit acquires Volpara as contemplated in the SIA and allows Volpara to sell Lunit's products immediately. New studies highlight use of Volpara algorithms. Volpara's robust algorithms have firmly established the company as a trusted research partner and industry leader.

Volpara technology has played a role in many European personalised screening and optimisation studies, such as the DENSE, TOMMY, To-Be trials, PROCAS I/II, and KARMA studies. Volpara's technology continues to be the gold standard for cutting edge research globally. For example, a recent study published in European Radiology, titled "Diagnostic performance of 3D automated breast ultrasound (3D-ABUS) in a clinical screening setting--a retrospective study," showcases the effectiveness of using Volpara volumetric breast density software to identify women appropriate for supplemental 3D-ABUS imaging.

This study retrospective analysed the use of digital breast tomosynthesis and 3D-ABUS from 2014 to 2022 to screen 1,555 women, of whom 96% were identified as having dense breast tissue (category C or D) using Volpara Scorecard. The study found malignancies in 2.4% of the screened women, with 27% of these cancers detected exclusively by 3D-ABUS. Volpara's suite of software will be on display in Booth #AI-21a.